Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line...
– Completed Phase 1 SAD and MAD trial of EDG-7500 in healthy volunteers; Dosing patients in Phase 2 CIRRUS-HCM trial of EDG-7500 in individuals with oHCM – – Continued to advance GRAND CANYON...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.95 | 11.3901869159 | 17.12 | 19.8392 | 16.6 | 1258015 | 17.79208037 | CS |
4 | -0.7 | -3.54071825999 | 19.77 | 21.04 | 16.6 | 869351 | 18.43058483 | CS |
12 | 1.3 | 7.31570061902 | 17.77 | 23.5 | 14.75 | 885336 | 18.78860347 | CS |
26 | 2.25 | 13.3769322235 | 16.82 | 23.5 | 14.75 | 734587 | 18.16978117 | CS |
52 | 12.66 | 197.503900156 | 6.41 | 23.5 | 5.12 | 709356 | 15.55648722 | CS |
156 | 2.03 | 11.9131455399 | 17.04 | 23.5 | 5.12 | 395831 | 13.78464431 | CS |
260 | -7.93 | -29.3703703704 | 27 | 40.49 | 5.12 | 364125 | 14.54042499 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.